Detalles de la búsqueda
1.
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Biol Blood Marrow Transplant
; 21(8): 1460-70, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25865646
2.
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Biol Blood Marrow Transplant
; 19(11): 1625-31, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24035782
Resultados
1 -
2
de 2
1
Próxima >
>>